BR112015024856A2 - métodos de determinação ou de monitoramento - Google Patents
métodos de determinação ou de monitoramentoInfo
- Publication number
- BR112015024856A2 BR112015024856A2 BR112015024856A BR112015024856A BR112015024856A2 BR 112015024856 A2 BR112015024856 A2 BR 112015024856A2 BR 112015024856 A BR112015024856 A BR 112015024856A BR 112015024856 A BR112015024856 A BR 112015024856A BR 112015024856 A2 BR112015024856 A2 BR 112015024856A2
- Authority
- BR
- Brazil
- Prior art keywords
- determination
- monitoring methods
- monitoring
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361805860P | 2013-03-27 | 2013-03-27 | |
US201361914619P | 2013-12-11 | 2013-12-11 | |
PCT/US2014/031825 WO2014160753A1 (en) | 2013-03-27 | 2014-03-26 | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015024856A2 true BR112015024856A2 (pt) | 2018-04-17 |
Family
ID=51625486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015024856A BR112015024856A2 (pt) | 2013-03-27 | 2014-03-26 | métodos de determinação ou de monitoramento |
Country Status (14)
Country | Link |
---|---|
US (3) | US20160209426A1 (pt) |
EP (3) | EP3933401A3 (pt) |
JP (4) | JP6615745B2 (pt) |
KR (1) | KR102175688B1 (pt) |
CN (1) | CN105143876B (pt) |
AU (3) | AU2014241552B2 (pt) |
BR (1) | BR112015024856A2 (pt) |
CA (1) | CA2904095A1 (pt) |
HK (1) | HK1218442A1 (pt) |
IL (2) | IL241185B (pt) |
MX (1) | MX2015011765A (pt) |
RU (1) | RU2015145610A (pt) |
SG (1) | SG11201507974RA (pt) |
WO (1) | WO2014160753A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015235986B2 (en) | 2014-03-27 | 2020-12-03 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
CA2969326A1 (en) * | 2014-12-02 | 2016-06-09 | Nestec S.A. | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease |
CA2916283A1 (en) * | 2015-01-09 | 2016-07-09 | Pfizer Inc. | Dosage regimen for madcam antagonists |
CN113209289A (zh) * | 2015-02-26 | 2021-08-06 | 豪夫迈·罗氏有限公司 | 治疗Crohn病的整联蛋白β7拮抗剂和方法 |
EP3329276A2 (en) * | 2015-07-27 | 2018-06-06 | H. Hoffnabb-La Roche Ag | Methods for diagnosing and treating inflammatory bowel disease |
AU2016306320B2 (en) * | 2015-08-11 | 2022-04-14 | Osaka University | Antibody |
EP3442578B1 (en) | 2016-04-15 | 2022-02-09 | The Board of Trustees of the Leland Stanford Junior University | Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer |
EP3532637A4 (en) * | 2016-10-27 | 2020-10-14 | Geneoscopy, LLC | PROOF PROCEDURE |
AR112336A1 (es) | 2017-07-14 | 2019-10-16 | Pfizer | ANTICUERPOS CONTRA MAdCAM |
CN107478563A (zh) * | 2017-07-19 | 2017-12-15 | 浙江省人民医院 | 一种基于流式细胞术检测结核特异性双细胞因子的方法 |
AU2019276577A1 (en) | 2018-06-01 | 2021-01-14 | Geneoscopy, Inc. | Detection method |
WO2020226498A1 (en) | 2019-05-07 | 2020-11-12 | Rijksuniversiteit Groningen | Biomarker, kit and method for predicting clinical responsiveness to therapy with an agent that targets alpha4beta7 integrin. |
IL300133A (en) | 2020-07-31 | 2023-03-01 | Genentech Inc | Anti-integrin antibody compositions in cell 7 and devices |
CN114200143B (zh) * | 2020-09-18 | 2024-04-02 | 上海透景诊断科技有限公司 | 血红蛋白和转铁蛋白在检测消化道出血中的应用 |
WO2023035000A1 (en) * | 2021-09-03 | 2023-03-09 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
CN116741409A (zh) * | 2023-05-12 | 2023-09-12 | 中国医学科学院北京协和医院 | 基于外周血生物标志物构建的模型在预测上消化道肿瘤化疗疗效中的应用 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4256833A (en) | 1979-01-08 | 1981-03-17 | Majid Ali | Enzyme immunoassay for allergic disorders |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
RO110397B1 (ro) | 1989-03-21 | 1996-01-30 | Immune Response Corp San Diego | Vaccin pentru prevenirea sau tratarea unor boli care rezulta din raspunsuri patogene, prin populatii de celule t specifice, procedeu de obtinere si metode de diagnostic si tratament cu acesta |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
ATE161850T1 (de) | 1989-07-19 | 1998-01-15 | Connetics Corp | T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
CA2086417C (en) | 1990-06-29 | 1999-07-06 | Biosource Technologies, Inc. | Melanin production by transformed organisms |
ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
WO1997033551A2 (en) | 1996-03-15 | 1997-09-18 | Millennium Pharmaceuticals | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
JP2007531735A (ja) | 2004-04-01 | 2007-11-08 | エラン ファーマシューティカルズ,インコーポレイテッド | ステロイド節約剤および該節約剤を使用する方法 |
PL1784426T3 (pl) * | 2004-09-03 | 2012-04-30 | Genentech Inc | Humanizowani antagoniści anty-beta7 i ich zastosowania |
AU2009246071B2 (en) * | 2008-05-16 | 2013-10-03 | Genentech, Inc. | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists |
CA2831732C (en) * | 2011-03-31 | 2019-12-31 | Genentech, Inc. | Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders |
ES2738305T3 (es) * | 2012-10-05 | 2020-01-21 | Hoffmann La Roche | Procedimientos para diagnosticar y tratar enfermedades inflamatorias intestinales |
KR101819414B1 (ko) * | 2016-08-10 | 2018-01-16 | 스미또모 가가꾸 가부시키가이샤 | 편광 필름 |
-
2014
- 2014-03-26 CA CA2904095A patent/CA2904095A1/en active Pending
- 2014-03-26 BR BR112015024856A patent/BR112015024856A2/pt not_active IP Right Cessation
- 2014-03-26 MX MX2015011765A patent/MX2015011765A/es active IP Right Grant
- 2014-03-26 AU AU2014241552A patent/AU2014241552B2/en active Active
- 2014-03-26 WO PCT/US2014/031825 patent/WO2014160753A1/en active Application Filing
- 2014-03-26 KR KR1020157030754A patent/KR102175688B1/ko active IP Right Grant
- 2014-03-26 SG SG11201507974RA patent/SG11201507974RA/en unknown
- 2014-03-26 CN CN201480019012.7A patent/CN105143876B/zh active Active
- 2014-03-26 EP EP21167425.4A patent/EP3933401A3/en active Pending
- 2014-03-26 EP EP18191598.4A patent/EP3495814A3/en not_active Withdrawn
- 2014-03-26 EP EP14774938.6A patent/EP2979087A4/en not_active Withdrawn
- 2014-03-26 RU RU2015145610A patent/RU2015145610A/ru not_active Application Discontinuation
- 2014-03-26 JP JP2016505542A patent/JP6615745B2/ja active Active
-
2015
- 2015-09-06 IL IL241185A patent/IL241185B/en active IP Right Grant
- 2015-09-18 US US14/858,226 patent/US20160209426A1/en not_active Abandoned
-
2016
- 2016-06-06 HK HK16106433.4A patent/HK1218442A1/zh unknown
-
2018
- 2018-07-17 AU AU2018206728A patent/AU2018206728B2/en active Active
- 2018-08-06 JP JP2018147604A patent/JP6740294B2/ja active Active
-
2019
- 2019-02-28 US US16/288,893 patent/US20200025775A1/en not_active Abandoned
-
2020
- 2020-04-12 IL IL273930A patent/IL273930A/en unknown
- 2020-07-22 JP JP2020125027A patent/JP7055176B2/ja active Active
-
2021
- 2021-01-22 AU AU2021200422A patent/AU2021200422A1/en not_active Abandoned
- 2021-12-15 US US17/552,211 patent/US20220357343A1/en not_active Abandoned
-
2022
- 2022-04-05 JP JP2022062883A patent/JP2022106732A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2022011I1 (no) | Tigolaner/Emodepsid/Praziquantel | |
BR112015024856A2 (pt) | métodos de determinação ou de monitoramento | |
DK2972351T3 (da) | Forbedrede analysemetoder | |
DK3043712T3 (da) | Hjerteovervågningssystem | |
BR112015028771A2 (pt) | conjunto de drenagem alongado | |
HK1211719A1 (en) | Customer-data analysis evaluation system | |
BR112015029436A2 (pt) | método de modificação de polímeros | |
DK3080385T3 (da) | Forbedret lukkeapparat | |
DE112014003851A5 (de) | Sensorbaueinheit | |
FI20135394L (fi) | Ikkunajärjestelmä | |
ES1096031Y (es) | Unidad de engatillado | |
ES1078548Y (es) | Percha de autoplanchado | |
TH1501001316B (th) | ระบบตรวจสังเกตยานพาหนะ | |
FI20135567L (fi) | Tekniikoita vaihteen kunnon valvomiseksi | |
UA26599S (uk) | Двері | |
UA26608S (uk) | Двері | |
UA26595S (uk) | Двері | |
UA26604S (uk) | Двері | |
UA26593S (uk) | Двері | |
UA26594S (uk) | Двері | |
UA26596S (uk) | Двері | |
UA26597S (uk) | Двері | |
UA26598S (uk) | Двері | |
UA26603S (uk) | Двері | |
UA26605S (uk) | Двері |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2560 DE 2020-01-28 |